ES2172937T3 - 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides. - Google Patents

21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.

Info

Publication number
ES2172937T3
ES2172937T3 ES98956833T ES98956833T ES2172937T3 ES 2172937 T3 ES2172937 T3 ES 2172937T3 ES 98956833 T ES98956833 T ES 98956833T ES 98956833 T ES98956833 T ES 98956833T ES 2172937 T3 ES2172937 T3 ES 2172937T3
Authority
ES
Spain
Prior art keywords
oxidoprogesterone
hydroxi
glucocorticoids
treat
excess
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956833T
Other languages
English (en)
Inventor
Gerardo Burton
Carlos Pedro Lantos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Application granted granted Critical
Publication of ES2172937T3 publication Critical patent/ES2172937T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

21-Hidroxi-6,19-oxidoprogesterona de fórmula I para uso como medicamento.
ES98956833T 1997-09-23 1998-09-22 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides. Expired - Lifetime ES2172937T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97116526A EP0903146A1 (en) 1997-09-23 1997-09-23 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid

Publications (1)

Publication Number Publication Date
ES2172937T3 true ES2172937T3 (es) 2002-10-01

Family

ID=8227390

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956833T Expired - Lifetime ES2172937T3 (es) 1997-09-23 1998-09-22 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides.

Country Status (13)

Country Link
US (1) US6303591B1 (es)
EP (2) EP0903146A1 (es)
AR (1) AR023008A1 (es)
AT (1) ATE215373T1 (es)
AU (1) AU738522B2 (es)
CA (1) CA2303817C (es)
DE (1) DE69804659T2 (es)
DK (1) DK1033990T3 (es)
ES (1) ES2172937T3 (es)
IL (1) IL135232A (es)
PT (1) PT1033990E (es)
WO (1) WO1999015181A1 (es)
ZA (1) ZA988674B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207610B1 (pl) 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
US7713989B2 (en) 2000-04-27 2010-05-11 Dow Robert L Glucocorticoid receptor modulators
DK1330468T3 (da) * 2000-09-18 2007-11-05 Serono Lab Svovlanaloger af 21 hydroxy-6,19-oxido-progesteron (21OH 6OP) til behandling af overskud af glucocorticoider
US7071328B2 (en) * 2000-09-18 2006-07-04 Applied Research System Ars Holding N.V. Method for the preparation of 21-hydroxy-6,19-oxidoprogesterone (21 oh-6op)
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
US8097606B2 (en) * 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
AU2007287070C1 (en) 2006-08-24 2013-02-14 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
WO2011150209A1 (en) 2010-05-26 2011-12-01 Corcept Therapeutics, Inc. Treatment of muscular dystrophy
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US12685719B2 (en) 2012-07-13 2026-07-21 University Of Tennessee Research Foundation Treatment of breast cancer with selective androgen receptor modulators and cyclin-dependent kinase 4/6 inhibitors
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
EP3733170A1 (en) 2012-07-13 2020-11-04 Oncternal Therapeutics, Inc. A method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
JP6754533B2 (ja) 2015-03-30 2020-09-16 コーセプト セラピューティクス， インコーポレイテッド 副腎機能不全を処置するための糖質コルチコイドと組み合わせた糖質コルチコイドレセプターアンタゴニストの使用
MX383318B (es) 2015-08-13 2025-03-13 Corcept Therapeutics Inc Metodo para diagnosticar de manera diferencial el sindrome de cushing dependiente de la corticotropina.
JP6765443B2 (ja) 2016-01-19 2020-10-07 コーセプト セラピューティクス， インコーポレイテッド 異所性クッシング症候群の鑑別診断
WO2018236749A2 (en) 2017-06-20 2018-12-27 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
CN113645979A (zh) * 2018-12-28 2021-11-12 熊猫咨询有限责任公司 短效选择性糖皮质激素受体调节剂
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118974A (en) * 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
AU747956B2 (en) * 1997-10-06 2002-05-30 Board Of Trustees Of The Leland Stanford Junior University Methods for treating psychosis associated with glucocorticoid related dysfunction

Also Published As

Publication number Publication date
AU738522B2 (en) 2001-09-20
PT1033990E (pt) 2002-07-31
US6303591B1 (en) 2001-10-16
IL135232A0 (en) 2001-05-20
CA2303817A1 (en) 1999-04-01
DE69804659T2 (de) 2002-10-02
WO1999015181A1 (en) 1999-04-01
IL135232A (en) 2005-05-17
ATE215373T1 (de) 2002-04-15
EP1033990B1 (en) 2002-04-03
EP1033990A1 (en) 2000-09-13
EP0903146A1 (en) 1999-03-24
AR023008A1 (es) 2002-09-04
AU1334199A (en) 1999-04-12
ZA988674B (en) 1999-06-28
CA2303817C (en) 2008-04-01
DK1033990T3 (da) 2002-07-08
DE69804659D1 (de) 2002-05-08

Similar Documents

Publication Publication Date Title
MX9304819A (es) Nuevos derivados de xantina y procedimiento para su preparacion.
SV1995000045A (es) Benzoxazolil- y benzotiazoliloxazolidinonas, ref. le a 30616-sv
MX9700885A (es) Nuevas heteroariloxazolidinonas.
DOP2000000109A (es) Derivados de tiazolilamida
SV1995000042A (es) Heteroaril-oxazolidinonas de 5 eslabones ref. le a 30523-sv
HN1999000124A (es) Derivados de pirazol substituido.
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
NO965516D0 (no) Sterolderivater anvendt til regulering av meiose
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
IT1285770B1 (it) Composti corticoidei
ES2183180T3 (es) Nuevos derivados de guanidina, procedimientos para su preparacion y su uso como medicamento.
ES2184131T3 (es) Derivados de benzamidina y su utilizacion como medicamentos con efecto antagonista de ltb4.
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
ES2178055T3 (es) Derivados aminicos substituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
UY26133A1 (es) Derivado sustituido de pirazol.
BR0110087A (pt) Compostos para modular proliferação celular
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
ES2167721T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de la dermatitis seborreica.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
BR0016781A (pt) Bases de 1-naftol e 2-naftol - mannich substituìdas
AR023374A1 (es) Derivados de 3-amino-3-arilpropano-1-ol. su preparacion y uso
AR021616A1 (es) Cicloheptenos sustituidos, procedimiento para su preparacion y uso de los mismos.
ATE275551T1 (de) Halogenpyrimidine

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1033990

Country of ref document: ES